Drug class in one race
BRAF V600E drugs for Non-Small Cell Lung Cancer
2 tracked BRAF V600E drugs in the Non-Small Cell Lung Cancer race. The class explanation lives on the BRAF V600E page; the full indication pipeline across every mechanism is on the Non-Small Cell Lung Cancer page.
1 approved / phase 41 Phase 2
Head-to-head evidence: Encorafenib vs HLX208